USA – The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have opened separate investigations into Biogen Inc and its Alzheimer’s medication, Aduhelm (aducanumab). According to the…
Read MoreMore Federal regulators launch probe into Biogen’s Aduhelm
